New England Journal of Medicine· 2016Q1· Clinical trial
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- 2,055citations
- Q1SCImago
- 2016year
Short summary
In two Phase 3 trials, dupilumab significantly improved moderate-to-severe atopic dermatitis symptoms compared to placebo, with 36-38% of patients achieving clear or almost clear skin after 16 weeks.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Dermatology
DermatologyMedicine